CD8A and neoplasm: All enrolled 15 patients had PD-L1-negative (assessed by VENTANA PD-L1 SP263 assay) disease, and evaluable pretreatment and on‐treatment tumor biopsies (n = 5) had sparse CD8 cell infiltration.